ArticleMicrobial cell factories2019
Integration of a multi-step heterologous pathway in Saccharomyces cerevisiae for the production of abscisic acid.
Article in Microbial cell factories, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 42 citations in OpenAlex.
- Resolution of the ABA Biosynthesis Controversy: Discovery of a Dihydroxylating Terpene Synthase and Its Convergent Evolution.ACS chemical biology · 2026Article
- Engineering Yarrowia Lipolytica for De Novo Biosynthesis of Abscisic Acid.Biotechnology journal · 2026Article
- Engineering Saccharomyces cerevisiae to improve heterologous abscisic acid production.Microbial cell factories · 2026Article
- Automated Strain Construction for Biosynthetic Pathway Screening in Yeast.ACS synthetic biology · 2025Article
- Multi-step pathway engineering in probioticMetabolic engineering communications · 2025Article
- Metabolic Engineering of a Serotonin Overproducing Saccharomyces cerevisiae Strain.Microbial biotechnology · 2025Article
- Systematic metabolic engineering ofSynthetic and systems biotechnology · 2025Article
- Engineering strategies for enhanced 1', 4'-trans-ABA diol production by Botrytis cinerea.Microbial cell factories · 2024Article
- From Genes to Molecules, Secondary Metabolism inPlants (Basel, Switzerland) · 2023Review
- Production of abscisic acid in the oleaginous yeast Yarrowia lipolytica.FEMS yeast research · 2022Article
- Toward improved terpenoids biosynthesis: strategies to enhance the capabilities of cell factories.Bioresources and bioprocessing · 2022Review
- Diversifying Isoprenoid PlatformsFrontiers in microbiology · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe sesquiterpenoid abscisic acid (ABA) is mostly known for regulating developmental processes and abiotic stress responses in higher plants. Recent studies show that ABA also exhibits a variety of pharmacological activities. Affordable and sustainable production will be required to utilize the compound in agriculture and as a potential pharmaceutical. Saccharomyces cerevisiae is an established workhorse for the biotechnological production of chemicals. In this study, we constructed and characterised an ABA-producing S. cerevisiae strain using the ABA biosynthetic pathway from Botrytis cinerea.
resultsExpression of the B. cinerea genes bcaba1, bcaba2, bcaba3 and bcaba4 was sufficient to establish ABA production in the heterologous host. We characterised the ABA-producing strain further by monitoring ABA production over time and, since the pathway contains two cytochrome P450 enzymes, by investigating the effects of overexpressing the native S. cerevisiae or the B. cinerea cytochrome P450 reductase. Both, overexpression of the native or heterologous cytochrome P450 reductase, led to increased ABA titres. We were able to show that ABA production was not affected by precursor or NADPH supply, which suggested that the heterologous enzymes were limiting the flux towards the product. The B. cinerea cytochrome P450 monooxygenases BcABA1 and BcABA2 were identified as pathway bottlenecks and balancing the expression levels of the pathway enzymes resulted in 4.1-fold increased ABA titres while reducing by-product formation.
conclusionThis work represents the first step towards a heterologous ABA cell factory for the commercially relevant sesquiterpenoid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.